1099 related articles for article (PubMed ID: 11408600)
21. Modulation by mu-opioid agonists of guanosine-5'-O-(3-[35S]thio)triphosphate binding to membranes from human neuroblastoma SH-SY5Y cells.
Traynor JR; Nahorski SR
Mol Pharmacol; 1995 Apr; 47(4):848-54. PubMed ID: 7723747
[TBL] [Abstract][Full Text] [Related]
22. Relationship of mu opioid receptor binding to activation of G-proteins in specific rat brain regions.
Maher CE; Selley DE; Childers SR
Biochem Pharmacol; 2000 Jun; 59(11):1395-401. PubMed ID: 10751548
[TBL] [Abstract][Full Text] [Related]
23. The spinal antinociceptive effects of endomorphins in rats: behavioral and G protein functional studies.
Xie H; Woods JH; Traynor JR; Ko MC
Anesth Analg; 2008 Jun; 106(6):1873-81. PubMed ID: 18499626
[TBL] [Abstract][Full Text] [Related]
24. Agonist-induced functional desensitization of the mu-opioid receptor is mediated by loss of membrane receptors rather than uncoupling from G protein.
Pak Y; Kouvelas A; Scheideler MA; Rasmussen J; O'Dowd BF; George SR
Mol Pharmacol; 1996 Nov; 50(5):1214-22. PubMed ID: 8913353
[TBL] [Abstract][Full Text] [Related]
25. Differential opioid agonist regulation of the mouse mu opioid receptor.
Blake AD; Bot G; Freeman JC; Reisine T
J Biol Chem; 1997 Jan; 272(2):782-90. PubMed ID: 8995364
[TBL] [Abstract][Full Text] [Related]
26. [(35)S]GTPĪ³S binding and opioid tolerance and efficacy in mouse spinal cord.
Madia PA; Navani DM; Yoburn BC
Pharmacol Biochem Behav; 2012 Mar; 101(1):155-65. PubMed ID: 22108651
[TBL] [Abstract][Full Text] [Related]
27. Opioid receptor-coupled G-proteins in rat locus coeruleus membranes: decrease in activity after chronic morphine treatment.
Selley DE; Nestler EJ; Breivogel CS; Childers SR
Brain Res; 1997 Jan; 746(1-2):10-8. PubMed ID: 9037478
[TBL] [Abstract][Full Text] [Related]
28. Tolerance to mu-opioid agonists in human neuroblastoma SH-SY5Y cells as determined by changes in guanosine-5'-O-(3-[35S]-thio)triphosphate binding.
Elliott J; Guo L; Traynor JR
Br J Pharmacol; 1997 Aug; 121(7):1422-8. PubMed ID: 9257923
[TBL] [Abstract][Full Text] [Related]
29. Opioid agonist and antagonist treatment differentially regulates immunoreactive mu-opioid receptors and dynamin-2 in vivo.
Yoburn BC; Purohit V; Patel K; Zhang Q
Eur J Pharmacol; 2004 Sep; 498(1-3):87-96. PubMed ID: 15363980
[TBL] [Abstract][Full Text] [Related]
30. Ca2+ channel and adenylyl cyclase modulation by cloned mu-opioid receptors in GH3 cells.
Piros ET; Prather PL; Loh HH; Law PY; Evans CJ; Hales TG
Mol Pharmacol; 1995 May; 47(5):1041-9. PubMed ID: 7746271
[TBL] [Abstract][Full Text] [Related]
31. In vivo pharmacological characterization of SoRI 9409, a nonpeptidic opioid mu-agonist/delta-antagonist that produces limited antinociceptive tolerance and attenuates morphine physical dependence.
Wells JL; Bartlett JL; Ananthan S; Bilsky EJ
J Pharmacol Exp Ther; 2001 May; 297(2):597-605. PubMed ID: 11303048
[TBL] [Abstract][Full Text] [Related]
32. Effects of chronic morphine exposure on opioid inhibition of adenylyl cyclase in 7315c cell membranes: a useful model for the study of tolerance at mu opioid receptors.
Puttfarcken PS; Werling LL; Cox BM
Mol Pharmacol; 1988 May; 33(5):520-7. PubMed ID: 2835651
[TBL] [Abstract][Full Text] [Related]
33. Absence of G-protein activation by mu-opioid receptor agonists in the spinal cord of mu-opioid receptor knockout mice.
Narita M; Mizoguchi H; Narita M; Sora I; Uhl GR; Tseng LF
Br J Pharmacol; 1999 Jan; 126(2):451-6. PubMed ID: 10077238
[TBL] [Abstract][Full Text] [Related]
34. Internalization and recycling of human mu opioid receptors expressed in Sf9 insect cells.
Chen LE; Gao C; Chen J; Xu XJ; Zhou DH; Chi ZQ
Life Sci; 2003 May; 73(1):115-28. PubMed ID: 12726892
[TBL] [Abstract][Full Text] [Related]
35. mu-Opioid receptor-stimulated guanosine-5'-O-(gamma-thio)-triphosphate binding in rat thalamus and cultured cell lines: signal transduction mechanisms underlying agonist efficacy.
Selley DE; Sim LJ; Xiao R; Liu Q; Childers SR
Mol Pharmacol; 1997 Jan; 51(1):87-96. PubMed ID: 9016350
[TBL] [Abstract][Full Text] [Related]
36. Role of protein kinase C (PKC) in agonist-induced mu-opioid receptor down-regulation: II. Activation and involvement of the alpha, epsilon, and zeta isoforms of PKC.
Kramer HK; Simon EJ
J Neurochem; 1999 Feb; 72(2):594-604. PubMed ID: 9930731
[TBL] [Abstract][Full Text] [Related]
37. Effects of intracerebroventricular administration of beta-funaltrexamine on DAMGO-stimulated [35S]GTP-gamma-S binding in rat brain sections.
Martin TJ; Sim LJ; Selley DE; deMontis MG; Childers SR
Synapse; 1997 Nov; 27(3):177-82. PubMed ID: 9329153
[TBL] [Abstract][Full Text] [Related]
38. Nucleoside diphosphate kinase associated with membranes modulates mu-opioid receptor-mediated [35S]GTPgammaS binding and agonist binding to mu-opioid receptor.
Zhang D; Li JG; Chen C; Liu-Chen LY
Eur J Pharmacol; 1999 Jul; 377(2-3):223-31. PubMed ID: 10456435
[TBL] [Abstract][Full Text] [Related]
39. Opioid agonists have different efficacy profiles for G protein activation, rapid desensitization, and endocytosis of mu-opioid receptors.
Borgland SL; Connor M; Osborne PB; Furness JB; Christie MJ
J Biol Chem; 2003 May; 278(21):18776-84. PubMed ID: 12642578
[TBL] [Abstract][Full Text] [Related]
40. Agonist-induced mu opioid receptor phosphorylation and functional desensitization in rat thalamus.
Deng HB; Yu Y; Wang H; Guang W; Wang JB
Brain Res; 2001 Apr; 898(2):204-14. PubMed ID: 11306006
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
